MedPath

Feasibility of Multi-gene Panel Testing at the Time of Diagnosis for Patients With Ovarian Cancer

Completed
Conditions
Ovarian Cancer
Registration Number
NCT03656809
Lead Sponsor
NYU Langone Health
Brief Summary

The purpose of this study is to determine the feasibility of routine referral to genetic counseling for all patients with a new diagnosis of epithelial ovarian, primary peritoneal or fallopian tube cancer.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
125
Inclusion Criteria
  • All subjects must have a new diagnosis of epithelial ovarian, primary peritoneal, fallopian tube or extra- uterine mullerian cancer.
  • All subjects must have either undergone primary surgery or be planning neoadjuvant chemotherapy for the treatment of ovarian, primary peritoneal or fallopian tube cancer.
  • All subjects must be able to comprehend and communicate in English.
  • All subjects must agree to participate.
  • A previous diagnosis of cancer is not an exclusion criterion.
  • Previous genetic screening is not an exclusion criterion.
Read More
Exclusion Criteria
  • Patients who do not meet the above inclusion criteria.
  • Patients with a diagnosis of a low malignant potential mullerian tumor.
  • Patients who are not proficient in English language because the survey aspect of this study is comprised of 4 validated surveys that are only available in English language.
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Feasibility of timely routine referral to genetic counseling for all patients with a new diagnosis of epithelial ovarian, primary peritoneal or Fallopian tube cancer.9 Months
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

New York University School of Medicine

🇺🇸

New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath